Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions

Curr Oncol Rep. 2009 Jan;11(1):62-7. doi: 10.1007/s11912-009-0010-x.

Abstract

Oligodendrogliomas account for a small subset of all gliomas, but they often are more sensitive to treatment than other glioma subtypes. In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic loss of 1p/19q (1p/19q loss), correlates with patient outcome in large-scale prospective clinical trials. However, the incorporation of 1p/19q status into clinical practice remains controversial. Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss.

Publication types

  • Review

MeSH terms

  • Alleles
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / therapy*
  • Chromosome Deletion
  • Chromosome Mapping
  • Chromosomes, Human, Pair 1 / genetics
  • Chromosomes, Human, Pair 19 / genetics
  • DNA Methylation
  • ErbB Receptors / metabolism
  • Genes, p53
  • Humans
  • Mutation
  • Oligodendroglioma / diagnosis*
  • Oligodendroglioma / genetics*
  • Oligodendroglioma / therapy*
  • Platelet-Derived Growth Factor / genetics
  • Platelet-Derived Growth Factor / metabolism
  • Prognosis
  • Receptors, Platelet-Derived Growth Factor / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Platelet-Derived Growth Factor
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • ErbB Receptors
  • Receptors, Platelet-Derived Growth Factor